gemfibrozil has been researched along with Innate Inflammatory Response in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is not known whether PPAR-alpha agonist gemfibrozil is able to exert rapidly its lipid modulating, potential antiinflammatory and antithrombotic effects in patients with non-ST elevation acute coronary syndrome (NSTEACS), as some other lipid lowering drugs e." | 9.12 | [Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor]. ( Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA, 2006) |
| "Nephrotoxicity is a significant side effect of doxorubicin (DXN) treatment." | 5.56 | Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation. ( Fatemi, I; Goudarzi, M; Hosseinzadeh, A; Karimi, MA; Khalili, HR; Khodayar, MJ; Mehrzadi, S, 2020) |
| "It is not known whether PPAR-alpha agonist gemfibrozil is able to exert rapidly its lipid modulating, potential antiinflammatory and antithrombotic effects in patients with non-ST elevation acute coronary syndrome (NSTEACS), as some other lipid lowering drugs e." | 5.12 | [Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor]. ( Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA, 2006) |
| " This study aimed to evaluate the effect of fenofibrate and gemfibrozil on inflammation in macrophages and reveal pathways these agents may affect." | 3.81 | PPARα agonists inhibit inflammatory activation of macrophages through upregulation of β-defensin 1. ( Ann, SJ; Chung, JH; Jang, J; Kang, SM; Kim, SH; Lee, SH; Park, BH; Park, S, 2015) |
| "Nephrotoxicity is a significant side effect of doxorubicin (DXN) treatment." | 1.56 | Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation. ( Fatemi, I; Goudarzi, M; Hosseinzadeh, A; Karimi, MA; Khalili, HR; Khodayar, MJ; Mehrzadi, S, 2020) |
| " Previous results suggest that vascular dysfunction in OZR is associated with chronic reduction in vascular nitric-oxide (NO) bioavailability and chronic inflammation, both frequently associated with hypercholesterolemia." | 1.35 | Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. ( Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA, 2009) |
| "Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus." | 1.34 | Increased survival after gemfibrozil treatment of severe mouse influenza. ( Alleva, L; Alsharifi, M; Budd, A; Clark, I; Koskinen, A; Müllbacher, A; Smythe, V; Wood, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Budd, A | 1 |
| Alleva, L | 1 |
| Alsharifi, M | 1 |
| Koskinen, A | 1 |
| Smythe, V | 1 |
| Müllbacher, A | 1 |
| Wood, J | 1 |
| Clark, I | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Hosseinzadeh, A | 1 |
| Goudarzi, M | 1 |
| Fatemi, I | 1 |
| Khodayar, MJ | 1 |
| Mehrzadi, S | 1 |
| Khalili, HR | 1 |
| Karimi, MA | 1 |
| Luo, Y | 1 |
| Hu, CT | 1 |
| Qiao, F | 1 |
| Wang, XD | 1 |
| Qin, JG | 1 |
| Du, ZY | 1 |
| Chen, LQ | 1 |
| Ann, SJ | 1 |
| Chung, JH | 1 |
| Park, BH | 1 |
| Kim, SH | 1 |
| Jang, J | 1 |
| Park, S | 1 |
| Kang, SM | 1 |
| Lee, SH | 1 |
| Roy, A | 1 |
| Pahan, K | 1 |
| Goodwill, AG | 1 |
| Frisbee, SJ | 1 |
| Stapleton, PA | 1 |
| James, ME | 1 |
| Frisbee, JC | 1 |
| Peloso, GM | 1 |
| Demissie, S | 1 |
| Collins, D | 1 |
| Mirel, DB | 1 |
| Gabriel, SB | 1 |
| Cupples, LA | 1 |
| Robins, SJ | 1 |
| Schaefer, EJ | 1 |
| Brousseau, ME | 1 |
| Calkin, AC | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Allen, TJ | 1 |
| Vaulin, NA | 1 |
| Pokrovskaia, EV | 1 |
| Deev, AD | 1 |
| Gratsianskiĭ, NA | 1 |
| Guzik, TJ | 1 |
| Harrison, DG | 1 |
| Staels, B | 1 |
| Koenig, W | 1 |
| Habib, A | 1 |
| Merval, R | 1 |
| Lebret, M | 1 |
| Torra, IP | 1 |
| Delerive, P | 1 |
| Fadel, A | 1 |
| Chinetti, G | 1 |
| Fruchart, JC | 1 |
| Najib, J | 1 |
| Maclouf, J | 1 |
| Tedgui, A | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
2 reviews available for gemfibrozil and Innate Inflammatory Response
| Article | Year |
|---|---|
Gemfibrozil, stretching arms beyond lipid lowering.
Topics: Cell Communication; Cell Movement; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Infla | 2009 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
1 trial available for gemfibrozil and Innate Inflammatory Response
| Article | Year |
|---|---|
[Early use of gemfibrozil in patients with non ST Elevation acute coronary syndrome. Changes of markers of inflammation and von Willebrand factor].
Topics: Acute Disease; Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Coronary Disease; Electrocardiogra | 2006 |
10 other studies available for gemfibrozil and Innate Inflammatory Response
| Article | Year |
|---|---|
Increased survival after gemfibrozil treatment of severe mouse influenza.
Topics: Animals; Anti-Inflammatory Agents; Gemfibrozil; Hypolipidemic Agents; Inflammation; Influenza A Viru | 2007 |
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation.
Topics: Animals; Antibiotics, Antineoplastic; Cytochrome P-450 CYP2C8 Inhibitors; Doxorubicin; Gemfibrozil; | 2020 |
Gemfibrozil improves lipid metabolism in Nile tilapia Oreochromis niloticus fed a high-carbohydrate diet through peroxisome proliferator activated receptor-α activation.
Topics: Adipose Tissue; Animals; Antioxidants; Body Composition; Cichlids; Diet; Dietary Carbohydrates; Feed | 2020 |
PPARα agonists inhibit inflammatory activation of macrophages through upregulation of β-defensin 1.
Topics: Animals; Anti-Inflammatory Agents; beta-Defensins; Cell Line; Culture Media, Conditioned; Dose-Respo | 2015 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids | 2009 |
Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.
Topics: Aged; Alleles; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Genetic Predis | 2010 |
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.
Topics: Angiotensins; Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Diabetes Mellitus, Experiment | 2006 |
Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
Topics: Albuminuria; Angiotensin II; Animals; Atherosclerosis; Endothelium, Vascular; Fibrosis; Gemfibrozil; | 2007 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox | 1998 |